FreshPatents.com Logo


new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Immunomedics Inc
Immunomedics Inc_20100114
Immunomedics Inc_20100121

Popular
Companies


Web
Adobe patents
Akamai patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

Ticker Symbols

Immunomedics, Inc. patents


      
Recent patent applications related to Immunomedics, Inc.. Immunomedics, Inc. is listed as an Agent/Assignee. Note: Immunomedics, Inc. may have other listings under different names/spellings. We're not affiliated with Immunomedics, Inc., we're just tracking patents.

ARCHIVE: New 2014 2013 2012 2011 2010 2009 | Company Directory "I" | Immunomedics, Inc.-related inventors



Search recent Press Releases: Immunomedics, Inc.-related press releases
Count Application # Date Immunomedics, Inc. patents (updated weekly) - BOOKMARK this page
12014036992712/18/14 new patent  Camptothecin conjugates of anti-cd22 antibodies for treatment of b cell diseases
22014028686009/25/14Immunoconjugates with an intracellularly-cleavable linkage
32014028686109/25/14Rs7 antibodies
42014023420908/21/14Chimeric and humanized anti-histone antibodies
52014022717808/14/14Humanized anti-hla-dr antibodies
62014022717908/14/14Anti-mucin antibodies for early detection and treatment of pancreatic cancer
72014022718008/14/14Antibody-sn-38 immunoconjugates with a cl2a linker
82014022854108/14/14Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
92014021991408/07/14Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
102014021995608/07/14Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
112014021242507/31/14Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
122014019335907/10/14Ultrafiltration concentration of allotype selected antibodies for small-volume administration
132014017829406/26/14Ultrafiltration concentration of allotype selected antibodies for small-volume administration
142014017006506/19/14Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments
152014015427306/05/14Anthracycline-antibody conjugates for cancer therapy
162014014738205/29/14Immunotherapy of b cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
172014014092405/22/14Humanized l243 antibodies
182014012003505/01/14Rs7 antibodies
192014011286404/24/14Anti-mucin antibodies for early detection and treatment of pancreatic cancer
202014011286504/24/14Anti-cd19 antibodies
212014010581904/17/14In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
222014009925804/10/14Camptothecin-binding moiety conjugates
232014008683003/27/14Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r)
242014008683203/27/14Delivery system for cytotoxic drugs by bispecific antibody pretargeting
252014007962903/20/14Class i anti-cea antibodies and uses thereof
262014005806702/27/14Immunoconjugates with an intracellularly-cleavable linkage
272014004463902/13/14Antibody therapy
282014004464002/13/14Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
292014003754302/06/14Anti-pancreatic cancer antibodies
302014003826102/06/14Compositions and methods of use of immunotoxins comprising ranpirnase (rap) show potent cytotoxic activity
312014003828402/06/14Mammalian cell lines for increasing longevity and protein yield from a cell culture
322014001716801/16/14Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
332014001719701/16/14Anti-cd19 antibodies
342014000407801/02/14Immunoconjugates with an intracellularly-cleavable linkage
352013031582111/28/13Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
362013030917711/21/13In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
372013021656108/22/13Immunoconjugates with an intracellularly-cleavable linkage
382013020935608/15/13Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
392013021104408/15/13Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
402013017749807/11/13Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
412013017752607/11/13Camptothecin conjugates of anti-cd22 antibodies for treatment of b cell diseases
422013017106407/04/13Anti-cd74 immunoconjugates and methods of use
432013017106507/04/13In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
442013017117607/04/13Anthracycline-antibody conjugates for cancer therapy
452013016421406/27/13Antibody-based depletion of antigen-presenting cells and dendritic cells
462013016478306/27/13Mammalian cell lines for increasing longevity and protein yield from a cell culture
472013015669106/20/13Antibody therapy
482013014278706/06/13Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
492013014329606/06/13Delivery system for cytotoxic drugs by bispecific antibody pretargeting
502013012191305/16/13Anti-cd19 antibodies
512013012347305/16/13Bispecific antibody targeting a complement factor or complement regulatory protein
522013009503404/18/13Anti-cd74 immunoconjugates and methods
532013009045804/11/13Immunoconjugates with an intracellularly-cleavable linkage
542013007818203/28/13Structural variants of antibodies for improved therapeutic characteristics
552013007826303/28/13Anti-hla-dr antibodies suppress allogeneic and xenogeneic immune responses to organ transplants
562013007132003/21/13Immunotherapy of autoimmune disorders using antibodies which target b-cells
572013007140603/21/13Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments
582013007265903/21/13Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
592013003986102/14/13Dye conjugated peptides for fluorescent imaging
602013003449202/07/13Class i anti-cea antibodies and uses thereof
612012032856412/27/12Camptothecin-binding moiety conjugates
622012032863412/27/12Immunoconjugates with an intracellularly-cleavable linkage
632012032155312/20/12Ultrafiltration concentration of allotype selected antibodies for small-volume administration
642012028217811/08/12Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
652012027610011/01/12Compositions and methods of use of immunotoxins comprising ranpirnase (rap) show potent cytotoxic activity
662012023095309/13/12Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
672012021496908/23/12Methods and compositions for f-18 labeling of proteins, peptides and other molecules
682012019632608/02/12Mammalian cell lines for increasing longevity and protein yield from a cell culture
692012018954207/26/12Anti-cd19 antibodies
702012018347207/19/12Immunotherapy of b-cell malignancies using anti-cd22 antibodies
712012018355007/19/12Therapeutic using a bispecific antibody
722012014908506/14/12Fusion proteins containing recombinant cytotoxic rnases
732012014137206/07/12Rs7 antibodies
742012014137506/07/12Anti-mucin antibodies for early detection and treatment of pancreatic cancer
752012013492005/31/12Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
762012011455605/10/12Immunotherapy of autoimmune disorders using antibodies which target b-cells
772012010723505/03/12Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
782012008829904/12/12Mammalian cell lines for increasing longevity and protein yield from a cell culture
792012008261704/05/12Immunoconjugates with an intracellularly-cleavable linkage
802012007672703/29/12In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
812012006399303/15/12Therapeutic and diagnostic conjugates for use with multispecific antibodies
822012003979702/16/12Antibody therapy
832012004043102/16/12Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
842012003418502/09/12Anti-cd20 antibodies and fusion proteins therof and methods of use
852011031153112/22/11Immunotherapy of autoimmune disorders using antibodies which target b-cells
862011030563112/15/11Camptothecin conjugates of anti-cd22 antibodies for treatment of b cell diseases
872011030006612/08/11Combination therapy with anti-cd74 antibodies provides enhanced toxicity to malignancies, autoimmune disease and other diseases
882011029351312/01/11Immunoconjugates with an intracellularly-cleavable linkage
892011028691811/24/11Immunotherapy of autoimmune disorders using antibodies which target b-cells
902011028080111/17/11Methods and compositions for f-18 labeling of proteins, peptides and other molecules
912011027470411/10/11Compositions and methods of use of immunotoxins comprising ranpirnase (rap) show potent cytotoxic activity
922011025605310/20/11Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to b-cell lymphomas and other diseases
932011024384110/06/11Antibody-based depletion of antigen-presenting cells and dendritic cells
942011024454610/06/11Internalizing anti-cd74 antibodies and methods of use
952011023630409/29/11Structural variants of antibodies for improved therapeutic characteristics
962011023640409/29/11Methods for protein expression in mammalian cells in serum-free medium
972011022940709/22/11Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
982011022364509/15/11Multivalent carriers of bi-specific antibodies
992011019502308/11/11Internalizing anti-cd74 antibodies and methods of use
1002011018908508/04/11Antibody therapy
1012011018926808/04/11Inhibition of placenta growth factor (plgf) mediated metastasis and/or angiogenesis
1022011017112607/14/11Enhanced cytotoxicity of anti-cd74 and anti-hla-dr antibodies with interferon-gamma
1032011016507207/07/11Detection of early-stage pancreatic adenocarcinoma
1042011016507307/07/11Immunotherapy of b-cell malignancies using anti-cd22 antibodies
1052011011701005/19/11Methods and compositions for administering therapeutic and diagnostic agents
1062011011710505/19/11Method of treating immune disease using b-cell antibodies
1072011011085405/12/11Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
1082011007623303/31/11Delivery system for cytotoxic drugs by bispecific antibody pretargeting
1092011007015503/24/11Anti-cd74 immunoconjugates and methods
1102011007015603/24/11Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
1112011006465303/17/11Class i anti-cea antibodies and uses thereof
1122011005248903/03/11Anti-cd19 antibodies
1132010031116212/09/10Mammalian cell lines for increasing longevity and protein yield from a cell culture
1142010028490611/11/10Internalizing anti-cd74 antibodies and methods of use
1152010027263610/28/10Anti-cd74 immunoconjugates and methods of use
1162010026649610/21/10Anti-cd74 immunoconjugates and methods of use
1172010026649710/21/10Internalizing anti-cd74 antibodies and methods of use
1182010023377909/16/10Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
1192010022688409/09/10Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r)
1202010022117509/02/10Antibody therapy
1212010022117709/02/10Rs7 antibodies
1222010021666208/26/10Inhibition of placenta growth factor (plgf) mediated metastasis and/or angiogenesis
1232010020296108/12/10D-amino acid peptides
1242010019626608/05/10Humanized anti-hla-dr antibodies
1252010019626708/05/10Humanized l243 antibodies
1262010019698908/05/10Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
1272010018964107/29/10Novel strategies for improved cancer vaccines
1282010015880206/24/10Chimeric, human and humanized anti-csap monoclonal antibodies
1292010015880306/24/10Production and use of novel peptide-based agents for use with bi-specific antibodies
1302010013662606/03/10Production and use of novel peptide-based agents for use with bi-specific antibodies
1312010010458904/29/10Immunoconjugates with an intracellularly-cleavable linkage
1322010007484003/25/10Anthracycline-antibody conjugates for cancer therapy
1332010006813603/18/10Anti-cd19 antibodies
1342010004054102/18/10Structural variants of antibodies for improved therapeutic characteristics
1352010003473802/11/10Structural variants of antibodies for improved therapeutic characteristics
1362010001504601/21/10Camptothecin-binding moiety conjugates
1372010001504801/21/10Internalizing anti-cd74 antibodies and methods of use
1382010000885501/14/10Production and use of novel peptide-based agents with bispecific antibodies
1392010000885801/14/10Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
1402009030458012/10/09Anti-pancreatic cancer antibodies
1412009029903312/03/09Methods and compositions for f-18 labeling of proteins, peptides and other molecules
1422009029109311/26/09Immunoconjugates with an intracellularly-cleavable linkage
1432009028575211/19/09Immunotherapy of b cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
1442009027464911/05/09Bispecific antibody point mutations for enhancing rate of clearance
1452009025273110/08/09Multivalent carriers of bi-specific antibodies
1462009025317910/08/09Mammalian cell lines for increasing longevity and protein yield from a cell culture
1472009024613010/01/09Methods and compositions for f-18 labeling of proteins, peptides and other molecules
1482009024613110/01/09Production and use of novel peptide-based agents for use with bi-specific antibodies
1492009024621410/01/09Fusion proteins containing recombinant cytotoxic rnases
1502009023875709/24/09Methods and compositions for administering therapeutic and diagnostic agents
1512009024003709/24/09Humanized antibodies and methods of humanizing antibodies
1522009018597407/23/09Chimeric, human and humanized anti-granulocyte antibodies and methods of use
1532009015516606/18/09Methods and compositions for f-18 labeling of proteins, peptides and other molecules
1542009015525306/18/09Anti-cd20 antibodies and fusion proteins therof and methods of use
1552009011114304/30/09Methods and compositions for mammalian cell lines for transfection and protein expression in serum-free medium
1562009009259804/09/09Antibody therapy
1572010001504801/21/10Internalizing anti-cd74 antibodies and methods of use
1582010000885801/14/10Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules


ARCHIVE: New 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Immunomedics, Inc. in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Immunomedics, Inc. with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###

     SHARE
  
         



Key IP Translations - Patent Translations